Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    21639810 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: vemurafenib and cobimetinib
2 Completed A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Ipilimumab and Fotemustine
3 Completed
Has Results
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Placebo;   Drug: Dacarbazine

Indicates status has not been verified in more than two years